2月24日 - ** 疗法开发商 Larimar Therapeutics LRMR.O股价盘前大涨 32%，至 3.71 美元
** 该公司称美国FDA授予其实验性疗法nomlabofusp突破性疗法称号
** 突破性疗法标签旨在加快开发和审查治疗严重疾病或未满足医疗需求的药物
** Nomlabofusp是一种蛋白质替代疗法，用于治疗患有神经退行性疾病弗里德雷氏共济失调的成人和儿童患者。
** 公司计划在 6 月前提交 Nomlabofusp 的上市申请
** 截至上次收盘，股价累计下跌 26.3%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.